Cargando…
Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis
BACKGROUND: The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported. OBJECTIVE: The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleos...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903621/ https://www.ncbi.nlm.nih.gov/pubmed/24475233 http://dx.doi.org/10.1371/journal.pone.0087103 |
_version_ | 1782301124023287808 |
---|---|
author | Liu, Zhu-Qing Han, Ying-Chao Zhang, Xi Chu, Li Fang, Jue-Min Zhao, Hua-Xin Chen, Yi-Jing Xu, Qing |
author_facet | Liu, Zhu-Qing Han, Ying-Chao Zhang, Xi Chu, Li Fang, Jue-Min Zhao, Hua-Xin Chen, Yi-Jing Xu, Qing |
author_sort | Liu, Zhu-Qing |
collection | PubMed |
description | BACKGROUND: The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported. OBJECTIVE: The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleoside transporter1 expression as a prognostic factor in pancreatic cancer receiving gemcitabine-based chemotherapy and to conduct a subsequent meta-analysis to quantify the overall prognostic effect. METHODS: Related studies were identified and evaluated for quality through multiple search strategies. Only studies analyzing pancreatic cancer receiving gemcitabine-based chemotherapy were eligible for inclusion. Data were collected from studies comparing overall, disease-free and progression-free survival (OS, DFS and PFS) in patients with low human equilibrative nucleoside transporter1 levels and those having high levels. The hazard ratio (HR) and its 95% confidence interval (95%CI) were used to assess the strength of associations. Hazard ratios greater than 1 reflect adverse survival associated with low human equilibrative nucleoside transporter1 levels. RESULTS: A total of 12 studies (n = 875) were involved in this meta-analysis (12 for OS, 5 for DFS, 3 for PFS). For overall and disease-free survival, the pooled HRs of human equilibrative nucleoside transporter1 were significant at 2.93 (95% confidence interval [95% CI], 2.37–3.64) and 2.67 (95% CI, 1.87–3.81), respectively. For progression-free survival, the pooled HR in higher human equilibrative nucleoside transporter1 expression in pancreatic cancer receiving gemcitabine-based chemotherapy was 2.76 (95% CI, 1.76–4.34). No evidence of significant heterogeneity or publication bias was seen in any of these studies. CONCLUSION: These results support the case for a low human equilibrative nucleoside transporter1 level representing a significant and reproducible marker of adverse prognosis in pancreatic cancer receiving gemcitabine-based chemotherapy. |
format | Online Article Text |
id | pubmed-3903621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-39036212014-01-28 Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis Liu, Zhu-Qing Han, Ying-Chao Zhang, Xi Chu, Li Fang, Jue-Min Zhao, Hua-Xin Chen, Yi-Jing Xu, Qing PLoS One Research Article BACKGROUND: The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported. OBJECTIVE: The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleoside transporter1 expression as a prognostic factor in pancreatic cancer receiving gemcitabine-based chemotherapy and to conduct a subsequent meta-analysis to quantify the overall prognostic effect. METHODS: Related studies were identified and evaluated for quality through multiple search strategies. Only studies analyzing pancreatic cancer receiving gemcitabine-based chemotherapy were eligible for inclusion. Data were collected from studies comparing overall, disease-free and progression-free survival (OS, DFS and PFS) in patients with low human equilibrative nucleoside transporter1 levels and those having high levels. The hazard ratio (HR) and its 95% confidence interval (95%CI) were used to assess the strength of associations. Hazard ratios greater than 1 reflect adverse survival associated with low human equilibrative nucleoside transporter1 levels. RESULTS: A total of 12 studies (n = 875) were involved in this meta-analysis (12 for OS, 5 for DFS, 3 for PFS). For overall and disease-free survival, the pooled HRs of human equilibrative nucleoside transporter1 were significant at 2.93 (95% confidence interval [95% CI], 2.37–3.64) and 2.67 (95% CI, 1.87–3.81), respectively. For progression-free survival, the pooled HR in higher human equilibrative nucleoside transporter1 expression in pancreatic cancer receiving gemcitabine-based chemotherapy was 2.76 (95% CI, 1.76–4.34). No evidence of significant heterogeneity or publication bias was seen in any of these studies. CONCLUSION: These results support the case for a low human equilibrative nucleoside transporter1 level representing a significant and reproducible marker of adverse prognosis in pancreatic cancer receiving gemcitabine-based chemotherapy. Public Library of Science 2014-01-27 /pmc/articles/PMC3903621/ /pubmed/24475233 http://dx.doi.org/10.1371/journal.pone.0087103 Text en © 2014 Liu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Liu, Zhu-Qing Han, Ying-Chao Zhang, Xi Chu, Li Fang, Jue-Min Zhao, Hua-Xin Chen, Yi-Jing Xu, Qing Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis |
title | Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis |
title_full | Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis |
title_fullStr | Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis |
title_full_unstemmed | Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis |
title_short | Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis |
title_sort | prognostic value of human equilibrative nucleosidetransporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903621/ https://www.ncbi.nlm.nih.gov/pubmed/24475233 http://dx.doi.org/10.1371/journal.pone.0087103 |
work_keys_str_mv | AT liuzhuqing prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT hanyingchao prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT zhangxi prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT chuli prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT fangjuemin prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT zhaohuaxin prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT chenyijing prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis AT xuqing prognosticvalueofhumanequilibrativenucleosidetransporter1inpancreaticcancerreceivinggemcitabinbasedchemotherapyametaanalysis |